Bio-Techne Q4 revenue up 5% to $301.3M; GAAP EPS $0.47 vs $0.38, adjusted EPS $0.55 vs $0.51

BIO-TECHNE Corp

2023-FY EPS reported $1.76 revenue$1,136,702,000

Full-year organic revenue grew 5% to $1.1B; GAAP EPS $1.76, adjusted EPS $1.99.
Diagnostics & Genomics segment organic growth 10% in Q4; full-year 8%.
ExoDx prostate test revenue surged 68% in Q4; GMP proteins up 58%.
Acquired Lunaphore (COMET spatial biology platform) – no deal value disclosed.
Quarterly dividend declared $0.08/share, payable Sept 1, record Aug 18.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.